EA200702064A1 - Новое анти-plgf антитело - Google Patents

Новое анти-plgf антитело

Info

Publication number
EA200702064A1
EA200702064A1 EA200702064A EA200702064A EA200702064A1 EA 200702064 A1 EA200702064 A1 EA 200702064A1 EA 200702064 A EA200702064 A EA 200702064A EA 200702064 A EA200702064 A EA 200702064A EA 200702064 A1 EA200702064 A1 EA 200702064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new anti
plgf antibody
fragments
plgf
antibody
Prior art date
Application number
EA200702064A
Other languages
English (en)
Other versions
EA013970B1 (ru
Inventor
Жан - Мари Стассен
Петер Кармелье
Дезире Коллен
Original Assignee
Тромбоджиникс Н.В.
Лайф Сайенсиз Рисерч Партнерз Взв
Вламс Интерюниверситайр Инститют Вор Биотехнологи Взв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тромбоджиникс Н.В., Лайф Сайенсиз Рисерч Партнерз Взв, Вламс Интерюниверситайр Инститют Вор Биотехнологи Взв filed Critical Тромбоджиникс Н.В.
Publication of EA200702064A1 publication Critical patent/EA200702064A1/ru
Publication of EA013970B1 publication Critical patent/EA013970B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к новым моноклональным антителам, нацеленным на PlGF, и их фрагментам и производным, более конкретно, к гуманизированным антителам и их фрагментам для применения в лечении и/или профилактике патологического ангиогенеза.
EA200702064A 2005-03-24 2006-03-24 Антитела к плацентарному фактору роста и способы их применения EA013970B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66476805P 2005-03-24 2005-03-24
PCT/BE2006/000023 WO2006099698A2 (en) 2005-03-24 2006-03-24 Novel anti-plgf antibody

Publications (2)

Publication Number Publication Date
EA200702064A1 true EA200702064A1 (ru) 2008-02-28
EA013970B1 EA013970B1 (ru) 2010-08-30

Family

ID=36928446

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702064A EA013970B1 (ru) 2005-03-24 2006-03-24 Антитела к плацентарному фактору роста и способы их применения

Country Status (27)

Country Link
US (3) US7875704B2 (ru)
EP (2) EP2447281B1 (ru)
JP (2) JP5164829B2 (ru)
KR (1) KR101314014B1 (ru)
CN (1) CN101184776B (ru)
AT (1) ATE549358T1 (ru)
AU (2) AU2006227571B8 (ru)
BR (1) BRPI0609151B8 (ru)
CA (1) CA2601267C (ru)
CY (1) CY1113224T1 (ru)
DK (1) DK1869085T3 (ru)
EA (1) EA013970B1 (ru)
ES (2) ES2565481T3 (ru)
HK (1) HK1116803A1 (ru)
HR (1) HRP20120477T1 (ru)
IL (1) IL185754A (ru)
ME (1) ME01446B (ru)
MX (1) MX2007011735A (ru)
NO (1) NO341877B1 (ru)
NZ (1) NZ561763A (ru)
PL (1) PL1869085T3 (ru)
PT (1) PT1869085E (ru)
RS (1) RS52372B (ru)
SI (1) SI1869085T1 (ru)
UA (1) UA94707C2 (ru)
WO (1) WO2006099698A2 (ru)
ZA (1) ZA200707258B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321069T1 (de) * 2000-05-12 2006-04-15 Vlaams Interuniv Inst Biotech Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
BRPI0609151B8 (pt) 2005-03-24 2021-05-25 Life Sciences Res Partners Vzw molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
KR20110014607A (ko) 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
DK2352761T3 (en) 2008-10-02 2016-10-03 Vib Vzw INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOMPOSITIVE LEUKEMIS
SG172355A1 (en) * 2008-12-23 2011-07-28 Genentech Inc Methods and compositions for diagnostic use in cancer patients
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CA2789564C (en) 2010-03-10 2019-08-13 F. Hoffmann-La Roche Ag Method for purifying immunoglobulin solutions
BR112012033423A2 (pt) * 2010-07-19 2016-10-25 Hoffmann La Roche métodos para melhorar a eficácia do tratamento de um regime de quimioterapia e in vitro, usos de bevacizumab e de sondas específicas, kit e uso de um polipeptídeo
AU2011285852B2 (en) 2010-08-03 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2012321082B2 (en) 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
AU2012362326A1 (en) 2011-12-30 2014-07-24 Abbvie Inc. Dual variable domain immunoglobulins against IL-13 and/or IL-17
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN104930353B (zh) * 2015-07-10 2017-08-15 浙江大学 一种城市供水管网的调压减漏评估系统
US20190031762A1 (en) 2016-03-10 2019-01-31 Thrombogenics Nv Posterior ocular fibrosis inhibition by antagonizing placental growth factor
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN109134650A (zh) * 2018-09-10 2019-01-04 宁波奥丞生物科技有限公司 抗人plgf单克隆抗体的制备方法
US20220228116A1 (en) 2019-05-28 2022-07-21 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
WO2020260595A1 (en) 2019-06-26 2020-12-30 Oncurious Nv Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
EP3936868A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin A ratio between plgf and sflt1 is predictive for neural invasion in patients suffering from pancreatic cancer
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
GB2616177A (en) * 2020-11-10 2023-08-30 Ningbo Aucheer Biotechnology Co Ltd Hybridoma cell strain 9C1, PLGF-1 monoclonal antibody, preparation method therefor and application thereof
CN112358546B (zh) * 2020-11-10 2022-04-01 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CN113999310A (zh) * 2020-12-30 2022-02-01 江苏普若维生物技术有限责任公司 一种plgf单克隆抗体、试剂盒、其制备方法和应用
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CA3211257A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2023118294A1 (en) 2021-12-22 2023-06-29 Vib Vzw Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5578704A (en) * 1992-04-03 1996-11-26 Genentech, Inc. Antibody to osteoclast alphavbeta3 ntegrin
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JP2000507915A (ja) 1995-10-23 2000-06-27 ハイアル・ファーマシューティカル・オーストラリア・リミテッド 遺伝子療法のためのｄｎａ担体としてのヒアルロン酸および異常な網膜血管新生を治療するためのｖｅｇｆアンチセンスｄｎａ
CA2266419A1 (en) 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
AU758353B2 (en) * 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
JPH11302193A (ja) * 1998-04-22 1999-11-02 Toagosei Co Ltd 血管新生阻害剤
CA2332336A1 (en) 1998-05-26 1999-12-02 Erik Depla Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
JP2001086982A (ja) 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
EP1252177A1 (en) * 2000-02-04 2002-10-30 Supratek Pharma, Inc. Ligand for vascular endothelial growth factor receptor
ATE321069T1 (de) * 2000-05-12 2006-04-15 Vlaams Interuniv Inst Biotech Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US7139817B1 (en) * 2001-06-12 2006-11-21 Network Appliance, Inc. Managing configuration information for multiple devices
JP2005508298A (ja) 2001-06-20 2005-03-31 イムクローン システムズ インコーポレイティド アテローム性動脈硬化症及び他の炎症性疾患を処置する方法
DE60310383T2 (de) 2002-01-29 2007-09-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Vorbeugung von gewebeadhäsion
EP2430923A1 (en) 2002-06-05 2012-03-21 Genentech, Inc. Compositions and methods for liver growth and liver protection
WO2004002524A1 (en) 2002-06-28 2004-01-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Placental growth factor as a target for the treatment of osteoporosis
CA2448769A1 (en) * 2002-11-08 2004-05-08 Primagen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
WO2004080408A2 (en) * 2003-03-10 2004-09-23 Callisto Pharmaceuticals, Inc. Method of treating cancer with azaspirane compositions
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
BRPI0609151B8 (pt) 2005-03-24 2021-05-25 Life Sciences Res Partners Vzw molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
US7867490B2 (en) * 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
DK2352761T3 (en) 2008-10-02 2016-10-03 Vib Vzw INHIBITION OF PLGF TO TREAT PHILADELPHIA CHROMOSOMPOSITIVE LEUKEMIS

Also Published As

Publication number Publication date
NO341877B1 (no) 2018-02-12
IL185754A0 (en) 2008-01-06
US8758748B2 (en) 2014-06-24
BRPI0609151B8 (pt) 2021-05-25
DK1869085T3 (da) 2012-06-18
KR20080016794A (ko) 2008-02-22
NO20074563L (no) 2007-12-18
IL185754A (en) 2013-02-28
AU2006227571A1 (en) 2006-09-28
ES2565481T3 (es) 2016-04-05
JP5164829B2 (ja) 2013-03-21
CA2601267C (en) 2014-02-18
US20140178397A1 (en) 2014-06-26
EP2447281A1 (en) 2012-05-02
BRPI0609151A2 (pt) 2010-02-17
CN101184776A (zh) 2008-05-21
EP2447281B1 (en) 2015-12-16
AU2011201340B2 (en) 2012-02-23
EA013970B1 (ru) 2010-08-30
CA2601267A1 (en) 2006-09-28
JP2008532557A (ja) 2008-08-21
MX2007011735A (es) 2008-03-14
EP1869085B1 (en) 2012-03-14
AU2006227571B2 (en) 2010-12-23
EP1869085A2 (en) 2007-12-26
PT1869085E (pt) 2012-06-01
HK1116803A1 (en) 2009-01-02
AU2006227571B8 (en) 2011-01-27
AU2011201340A1 (en) 2011-04-14
US7875704B2 (en) 2011-01-25
BRPI0609151B1 (pt) 2020-01-21
KR101314014B1 (ko) 2013-10-02
US20110123525A1 (en) 2011-05-26
US20080193455A1 (en) 2008-08-14
PL1869085T3 (pl) 2012-09-28
SI1869085T1 (sl) 2012-07-31
ME01446B (me) 2013-12-20
CN101184776B (zh) 2013-04-24
UA94707C2 (en) 2011-06-10
ATE549358T1 (de) 2012-03-15
US9085617B2 (en) 2015-07-21
RS52372B (en) 2012-12-31
ZA200707258B (en) 2008-06-25
ES2384110T3 (es) 2012-06-29
JP2012136522A (ja) 2012-07-19
WO2006099698A3 (en) 2006-11-30
WO2006099698A2 (en) 2006-09-28
NZ561763A (en) 2009-02-28
HRP20120477T1 (hr) 2012-07-31
CY1113224T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
EA200702064A1 (ru) Новое анти-plgf антитело
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
NL301089I2 (nl) imlifidase
CY1120365T1 (el) Αντισωματα εναντι της il-17
DE602006013029D1 (de) Anti-egfr-antikörper
UA92504C2 (en) Anti-myostatin monoclonal antibody
EA200802168A1 (ru) Гуманизированное антитело к с-kit
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
NO20076404L (no) Humaniserte anti-CD40 antistoffer og deres anvendelsesmetoder
ATE545657T1 (de) Tgf-beta antikörper
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
WO2005003169A3 (en) Modified antibody fab fragments
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
NO20073981L (no) Criptobindende molekyler
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
ITRM20040105A1 (it) Anticorpo monoclonale antitenascina umana.
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU